Is Inovio Pharmaceuticals efficiently growing its dividend?
Inovio Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Inovio Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,540.00 in company stock.
Is Inovio’s liquidity good enough?
Inovio has reasonable current liquidity; however, its lack of near-term catalysts is concerning. Inovio ( NASDAQ: INO) has flown high over the last few years, but is hovering at a share price of under $2.00 as I write on 07/16/2022.
What is the price targets for Inovio Pharmaceuticals (Invi)?
Inovio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings. According to analysts' consensus price target of $12.60, Inovio Pharmaceuticals has a forecasted upside of 279.5% from its current price of $3.32.
When is Inovio Pharmaceuticals'next quarterly announcement?
Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022. View our earnings forecast for Inovio Pharmaceuticals. How were Inovio Pharmaceuticals' earnings last quarter?
Is Inovio stock a buy or sell?
The Inovio Pharmaceuticals stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Will INO stock go back up?
Based on our forecasts, a long-term increase is expected, the "INO" stock price prognosis for 2027-06-30 is 3.316 USD. With a 5-year investment, the revenue is expected to be around +75.47%. Your current $100 investment may be up to $175.47 in 2027. Get It Now!
How high is inovio stock expected to go?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 3.50, with a high estimate of 8.00 and a low estimate of 2.00. The median estimate represents a +80.41% increase from the last price of 1.94.
Does inovio pay a dividend?
INO does not currently pay a dividend.
Is inovio undervalued?
The current market capitalization of $850 million includes some assumption of success, but since I expect VGX-3100 revenue to top $250 million annually at some point, in my view Inovio is currently undervalued. Positive Phase 2 glioblastoma results could also be a catalyst for a higher stock price.
Should I hold Inovio stock?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Annovis Bio stock.
Who owns Inovio stock?
Top 10 Owners of Inovio Pharmaceuticals IncStockholderStakeShares ownedBlackRock Fund Advisors6.74%15,433,492The Vanguard Group, Inc.4.77%10,917,466D. E. Shaw & Co. LP2.40%5,499,823Geode Capital Management LLC1.48%3,393,0336 more rows
Why is inovio stock down today?
Inovio stock plunges after U.S. government stops funding of Phase 3 trial of COVID-19 vaccine candidate. Shares of Inovio Pharmaceuticals Inc.
Is Inovio Pharmaceuticals stock a Buy, Sell or Hold?
Inovio Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 4 buy ratings, 6 hold ratings, an...
What was the 52-week low for Inovio Pharmaceuticals stock?
The low in the last 52 weeks of Inovio Pharmaceuticals stock was 1.51. According to the current price, Inovio Pharmaceuticals is 100.33% away from...
What was the 52-week high for Inovio Pharmaceuticals stock?
The high in the last 52 weeks of Inovio Pharmaceuticals stock was 9.96. According to the current price, Inovio Pharmaceuticals is 15.17% away from...
What are analysts forecasts for Inovio Pharmaceuticals stock?
The 12 analysts offering price forecasts for Inovio Pharmaceuticals have a median target of 16.25, with a high estimate of 45.00 and a low estimate...
Should I buy or sell Inovio Pharmaceuticals stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 5 ho...
What is Inovio Pharmaceuticals' stock price forecast for 2022?
5 Wall Street research analysts have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $3.00 to $35.0...
How has Inovio Pharmaceuticals' stock price performed in 2022?
Inovio Pharmaceuticals' stock was trading at $4.99 on January 1st, 2022. Since then, INO shares have decreased by 69.7% and is now trading at $1.51...
Are investors shorting Inovio Pharmaceuticals?
Inovio Pharmaceuticals saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 34,410,000 shares, a dro...
When is Inovio Pharmaceuticals' next earnings date?
Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for...
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earning...
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of s...
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the following people: Dr. J. Joseph Kim Ph.D. , CEO, Pres & Director (Age 53, Pay $1.31M) Mr. P...
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?
12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com . J. Joseph Kim has an approval rating of 82% among Inovio Pharm...
How much does Inovio make?
When did the 1-4 reverse split happen?
How much money does Inovio Pharmaceuticals make? Inovio Pharmaceuticals has a market capitalization of $2.02 billion and generates $7.41 million in revenue each year . The biopharmaceutical company earns $-166,410,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.
